Home › Funds › T. Rowe Price Investment Management, Inc. › CYTK

T. Rowe Price Investment Management, Inc. position in CYTK

CYTOKINETICS INC · Health Care

T. Rowe Price Investment Management, Inc. reported holding 18,912,704 shares of CYTK (CYTOKINETICS INC) in its Q3 2026 13F filing — a position valued at US$1.25B, representing 0.88% of its reported portfolio and ranking #22 among its reported holdings. T. Rowe Price Investment Management, Inc. has disclosed CYTK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)18.91M sh
Reported value held$1.25B
Portfolio Weight0.88%
First reportedQ3 2023
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How T. Rowe Price Investment Management, Inc.'s CYTK position evolved

T. Rowe Price Investment Management, Inc. first disclosed a stake in CYTK in Q3 2023 at 1,816,186 shares (US$53.5M). The position peaked in Q2 2026 at 18,718,498 shares, worth US$1.59B. Across 13 filings, T. Rowe Price Investment Management, Inc. increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 18,912,704 shares valued at US$1.25B — an increase of 194,206 shares quarter over quarter.. Notable position changes include a 130% increase in Q1 2024 (shares fell 23% over the following quarter), a 59% increase in Q2 2024 (shares fell 3% over the following quarter), a 77% increase in Q2 2025 (shares rose 66% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.82M $53.51M New
Q4 2023 2.23M $186.14M Add
Q1 2024 5.12M $359.07M Add
Q2 2024 8.14M $440.95M Add
Q3 2024 9.69M $511.63M Add
Q4 2024 10.75M $505.78M Add
Q1 2025 9.96M $400.10M Reduce
Q2 2025 17.60M $581.59M Add
Q3 2025 19.08M $1.05B Add
Q4 2025 17.72M $1.13B Reduce
Q1 2026 17.52M $1.15B Reduce
Q2 2026 18.72M $1.59B Add
Q3 2026 18.91M $1.25B Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC) is a Health Care company. 35 other funds we track also report a position in CYTK — the largest reported positions include Avoro Capital Advisors LLC (US$323.0M), Polar Capital Holdings Plc (US$227.7M), RTW INVESTMENTS, LP (US$188.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has T. Rowe Price Investment Management, Inc. held CYTK?

T. Rowe Price Investment Management, Inc. has disclosed CYTK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is T. Rowe Price Investment Management, Inc.'s current position in CYTK?

As of Q3 2026, T. Rowe Price Investment Management, Inc. holds 18.91M shares of CYTK (CYTOKINETICS INC), valued at $1.25B, representing 0.88% of its reported portfolio and ranking #22.

Has T. Rowe Price Investment Management, Inc. been buying or selling CYTK?

In the latest 13F filing (Q3 2026), T. Rowe Price Investment Management, Inc. increased its position in CYTK. The position peaked in Q2 2026 at 18.72M shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, RTW INVESTMENTS, LP, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.